Interpretable machine learning for predicting the response duration to Sintilimab plus chemotherapy in patients with advanced gastric or gastroesophageal junction cancer

BackgroundSintilimab plus chemotherapy has proven effective as a combination immunotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC). A multi-center study conducted in China revealed a median progression-free survival (PFS) of 7.1 months. However, the...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Dan-qi Wang, Wen-huan Xu, Xiao-wei Cheng, Lei Hua, Xiao-song Ge, Li Liu, Xiang Gao
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Frontiers Media S.A. 2024-05-01
Cyfres:	Frontiers in Immunology
Pynciau:	Sintilimab immunotherapy progression-free survival machine learning interpretability
Mynediad Ar-lein:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1407632/full
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!